Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

NCT07269249 · clinicaltrials.gov ↗
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute, Naples